College of Medicine, Hawler Medical University, Minara village A05, Erbil, Iraq.
College of pharmacy, Hawler Medical University, Erbil, Iraq.
BMC Pharmacol Toxicol. 2019 May 3;20(1):23. doi: 10.1186/s40360-019-0304-z.
The activation of neurohumoral compensatory mechanisms is a common physiological phenomenon in heart failure in order to make up for a failing heart, which will usually have a deteriorating effect on overall health condition. Many medications, such as neprilysin and angiotensin inhibitors, have recently been introduced to remediate neurohumoral changes. This study was conducted to evaluate the efficacy of the sacubitril-aliskiren combination versus the sacubitril-ramipril combination in the treatment of neurohumoral changes in rats with experimentally induced heart failure.
Thirty Wister rats were randomly assigned into five groups each of six rats, the first group was the control group. Intraperitoneal isoprenaline injections of 5 mg/kg/day for 1 week were used to induce experimental models of heart failure in rats of the rest of experimental groups. The second group served as a positive control. Rats in the third, fourth, and fifth groups received oral daily dose of sacubitril 30 mg/kg/day, sacubitril-aliskiren 30,10 mg/kg/day, and sacubitril-ramipril 30/10 mg/kg/day respectively, for 2 weeks.
Induction of heart failure in rats has significantly increased circulating NT-proBNP (980 ± 116.71 pg/ml), MMP9 (15.85 ± 0.57 ng/ml), troponin-I (3.09 ± 0.147 ng/ml), CK-MB (31.55 ± 1.69 ng/ml), renin (736 ± 45.8 pg/ml), urea (52.1 ± 1.57 mg/dl), and creatinine (0.92 ± 0.04 mg/dl). Significant decreases in glomerular filtration rate (7.031 ± 1.6 ml/hr./kg), urine flow (0.2761 ± 0.06 ml/h/kg), total solute excretion (0.11 ± 0.03 meq/m), and mean blood pressure (83.5 ± 2.6 mm hg) were seen in rats with heart failure. Rats treated with sacubitril combined with aliskiren or ramipril showed a statistically significant reduction of NT-proBNP, MMP9, troponin serum urea, and serum creatinine. Sacubitril-aliskiren or sacubitril-ramipril administration produced a significant increase in renin plasma level, total solute excretion, urine flow, and glomerular filtration rate.
Sacubitril in combination with aliskiren or with ramipril effectively reduced plasma cardiac biomarkers, such as CK-MB, MMP9, and NT-proBNP, in rats with heart failure. Both combinations showed significant remediation of renal function through increasing GFR, urine flow, and total solute excretion, as well as reducing plasma level of renin. Net results revealed that the sacubitril-aliskiren combination has similar remediating effects on neurohumoral changes compared to the sacubitril-ramipril combination.
神经体液补偿机制的激活是心力衰竭中常见的生理现象,目的是弥补衰竭的心脏,这通常会对整体健康状况产生恶化影响。最近引入了许多药物,如 Neprilysin 和血管紧张素抑制剂,以纠正神经体液变化。本研究旨在评估 sacubitril-aliskiren 联合与 sacubitril-ramipril 联合治疗实验性心力衰竭大鼠神经体液变化的疗效。
将 30 只 Wister 大鼠随机分为五组,每组 6 只,第一组为对照组。大鼠腹腔注射 5mg/kg/天的异丙肾上腺素,持续 1 周,以诱导心力衰竭实验模型。第二组作为阳性对照组。第三、第四和第五组大鼠分别每日口服 sacubitril 30mg/kg/天、 sacubitril-aliskiren 30,10mg/kg/天和 sacubitril-ramipril 30/10mg/kg/天,持续 2 周。
心力衰竭大鼠的循环 NT-proBNP(980±116.71pg/ml)、MMP9(15.85±0.57ng/ml)、肌钙蛋白 I(3.09±0.147ng/ml)、CK-MB(31.55±1.69ng/ml)、肾素(736±45.8pg/ml)、尿素(52.1±1.57mg/dl)和肌酐(0.92±0.04mg/dl)显著增加。心力衰竭大鼠肾小球滤过率(7.031±1.6ml/hr./kg)、尿流量(0.2761±0.06ml/h/kg)、总溶质排泄量(0.11±0.03meq/m)和平均血压(83.5±2.6mmHg)显著降低。用 sacubitril 联合 aliskiren 或 ramipril 治疗的大鼠,NT-proBNP、MMP9、肌钙蛋白血清尿素和血清肌酐明显减少。Sacubitril-aliskiren 或 sacubitril-ramipril 给药可显著增加血浆肾素水平、总溶质排泄量、尿流量和肾小球滤过率。
sacubitril 联合 aliskiren 或 ramipril 可有效降低心力衰竭大鼠的血浆心脏标志物,如 CK-MB、MMP9 和 NT-proBNP。两种联合用药均通过增加 GFR、尿流量和总溶质排泄量以及降低血浆肾素水平,显著改善肾功能。结果表明, sacubitril-aliskiren 联合用药对神经体液变化的改善作用与 sacubitril-ramipril 联合用药相似。